Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer
Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Novel Clinical Trials With ADCs in Gastric Cancer
Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.
Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd
Panelists share their perspective on the role of the broader, multidisciplinary healthcare team in managing toxicity associated with trastuzumab deruxtecan therapy.
T-DXd in HER2+ Gastric Cancer: Educating Patients About Risk of Diarrhea
Comprehensive insight on the optimal management of diarrhea associated with ADC therapy, with regard to patient education and monitoring during treatment.
Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea
Shifting focus to the second patient profile of HER2+ gastric cancer, key opinion leaders highlight the risk and management of diarrhea in this setting.
Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer
Panelists briefly review ongoing clinical trials with trastuzumab deruxtecan in the setting of HER2+ gastric cancers.
T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs
Focused discussion on the management of antibody drug conjugate–related adverse events in gastric cancer, with a focus on neutropenia.
First- and Second-Line Treatment Options for HER2+ Gastric Cancer
A broad overview of the treatment armamentarium for patients receiving first- or second-line therapy for HER2+ gastric cancer.
Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia
Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer
Before closing out their discussion on antibody drug conjugate use in breast cancer management, panelists consider ongoing clinical trials in this setting.
Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers
Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.
Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers
Shared insight on the clinical utility of trastuzumab emtansine in the second- and third-line settings of breast and gastric cancers.
Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy
Shifting focus to a patient profile of HER2+ metastatic breast cancer treated with trastuzumab emtansine, oncology nurse experts review risk of peripheral neuropathy and its management.
Sequencing Therapy in MBC in Second Line and Beyond
Closing out their conversation on the first patient profile, oncology nurse experts consider sequencing therapy following trastuzumab deruxtecan in both breast and GI cancers.
Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs
Comprehensive insight to the selection and education of patients for whom ADC therapy is an option in breast or gastric cancers, with regard for pulmonary risk status.
Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers
Focused conversation on the occurrence of interstitial lung disease in patients on antibody drug conjugate therapy for breast or gastric cancers.
Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers
Contextualizing the use of T-DXd in breast cancer and gastric cancers respectively, panelists highlight optimal management of adverse events in these settings.
Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD
After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
2 Clarke Drive Cranbury, NJ 08512